This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2021 Jun;108(6):566-570.

doi: 10.1016/j.bulcan.2021.02.014. Epub 2021 May 18.

FGFR alterations in urothelial carcinoma: Picking the right target

Paul Hubert¹, Zohair Selmani², Yohann Loriot³, Antoine Thiery-Vuillemin⁴

Affiliations

Affiliations

¹ University Hospital of Besançon, Department of Medical Oncology, Besançon, France.
² University Hospital of Besançon, Department of Oncobiology, Besançon, France.
³ Gustave Roussy, INSERM Unité 981, University of Paris-Saclay, Villejuif, France.
⁴ University Hospital of Besançon, Department of Medical Oncology, Besançon, France; Inserm, UMR1098, 25020 Besançon cedex, France. Electronic address: a.thieryvuillemin@mac.com.

PMID: 34020787
DOI: 10.1016/j.bulcan.2021.02.014

FGFR alterations in urothelial carcinoma: Picking the right target

Paul Hubert et al. Bull Cancer. 2021 Jun.

. 2021 Jun;108(6):566-570.

doi: 10.1016/j.bulcan.2021.02.014. Epub 2021 May 18.

Authors

Paul Hubert¹, Zohair Selmani², Yohann Loriot³, Antoine Thiery-Vuillemin⁴

Affiliations

¹ University Hospital of Besançon, Department of Medical Oncology, Besançon, France.
² University Hospital of Besançon, Department of Oncobiology, Besançon, France.
³ Gustave Roussy, INSERM Unité 981, University of Paris-Saclay, Villejuif, France.
⁴ University Hospital of Besançon, Department of Medical Oncology, Besançon, France; Inserm, UMR1098, 25020 Besançon cedex, France. Electronic address: a.thieryvuillemin@mac.com.

PMID: 34020787
DOI: 10.1016/j.bulcan.2021.02.014

No abstract available

Keywords: Anti-FGFR; Companion diagnostic; FGFR alterations; Targeted therapies; Urothelial carcinoma.

PubMed Disclaimer

Similar articles

Fibroblast growth factor receptor (FGFR) gene: pathogenesis and treatment implications in urothelial carcinoma of the bladder.
Al-Obaidy KI, Cheng L. Al-Obaidy KI, et al. J Clin Pathol. 2021 Aug;74(8):491-495. doi: 10.1136/jclinpath-2020-207115. Epub 2021 Mar 17. J Clin Pathol. 2021. PMID: 33731335 Review.
Fibroblast growth factor receptor (FGFR) inhibitors: A review of a novel therapeutic class.
Weaver A, Bossaer JB. Weaver A, et al. J Oncol Pharm Pract. 2021 Apr;27(3):702-710. doi: 10.1177/1078155220983425. Epub 2020 Dec 29. J Oncol Pharm Pract. 2021. PMID: 33375902 Review.
Erdafitinib for advanced urothelial carcinoma.
Burki TK. Burki TK. Lancet Oncol. 2019 Sep;20(9):e469. doi: 10.1016/S1470-2045(19)30522-4. Epub 2019 Aug 1. Lancet Oncol. 2019. PMID: 31378458 Clinical Trial. No abstract available.
Identifying fibroblast growth factor receptor genetic alterations using RNA-based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment.
Wang S, Burgess M, Major C, English A, Sweeney M, Hartmann A. Wang S, et al. J Pathol Clin Res. 2020 Jul;6(3):207-214. doi: 10.1002/cjp2.163. Epub 2020 Apr 18. J Pathol Clin Res. 2020. PMID: 32304281 Free PMC article.
Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
Schuler M, Cho BC, Sayehli CM, Navarro A, Soo RA, Richly H, Cassier PA, Tai D, Penel N, Nogova L, Park SH, Schostak M, Gajate P, Cathomas R, Rajagopalan P, Grevel J, Bender S, Boix O, Nogai H, Ocker M, Ellinghaus P, Joerger M. Schuler M, et al. Lancet Oncol. 2019 Oct;20(10):1454-1466. doi: 10.1016/S1470-2045(19)30412-7. Epub 2019 Aug 9. Lancet Oncol. 2019. PMID: 31405822 Clinical Trial.

See all similar articles

Cited by

Genomic Profiling and Molecular Characterisation of Metastatic Urothelial Carcinoma.
Pezzicoli G, Ciciriello F, Musci V, Minei S, Biasi A, Ragno A, Cafforio P, Rizzo M. Pezzicoli G, et al. Medicina (Kaunas). 2024 Mar 31;60(4):585. doi: 10.3390/medicina60040585. Medicina (Kaunas). 2024. PMID: 38674231 Free PMC article. Review.
Genomics and Immunomics in the Treatment of Urothelial Carcinoma.
Mollica V, Massari F, Rizzo A, Ferrara R, Menta AK, Adashek JJ. Mollica V, et al. Curr Oncol. 2022 May 12;29(5):3499-3518. doi: 10.3390/curroncol29050283. Curr Oncol. 2022. PMID: 35621673 Free PMC article. Review.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information